SecBot SecBot
424B4 ·Filed Nov 13, 2026

ABVC

ABVC BIOPHARMA, INC.
BEARISH
Impact 6/10
Horizonweeks Processed3d 7h ago SEC0001213900-26-119790
Actionable Insight ▼ Bearish

Monitor whether the company can secure additional financing given the going concern warning and depleted cash position. Watch for further dilution from the convertible notes and warrants, and any updates on clinical trial progress that could generate revenue.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

ABVC drug pipeline →

ABV-1504

● Neutral Named in this 424B4
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

Executive Summary

ABVC BioPharma filed four 424B4 prospectus supplements on November 13, 2026, covering 11,714,683 shares of common stock plus 4,400,187 shares underlying warrants (3,400,187 and 1,000,000), all incorporating the company's Q3 2026 Form 10-Q. The 10-Q shows zero revenue, a $3.89 million net loss for the nine months ended September 30, 2026, a $5.79 million working capital deficit, and substantial doubt about the company's ability to continue as a going concern. The company raised $3.39 million gross via an October 30, 2026 convertible note private placement (net $2.22 million) and settled $625,000 with Lind, but the ongoing dilution and liquidity crisis dominate the picture.

Key Facts

  • Four 424B4 supplements filed Nov 13, 2026: 11,714,683 common shares plus 4,400,187 shares underlying warrants (3,400,187 + 1,000,000)
  • Q3 2026 (nine months ended Sept 30, 2026): revenue $0, net loss $3,890,550, working capital deficit $5,788,170
  • Cash and cash equivalents fell to $11,294 as of Sept 30, 2026 from $681,480 at Dec 31, 2025
  • Substantial doubt about ability to continue as a going concern
  • Oct 30, 2026: raised $3,387,500 gross ($4,106,060 principal) via OID senior convertible notes, net $2,216,927 to company
  • Oct 26, 2026: Lind settlement agreement, $625,000 payment, Lind warrant increased 20% to 477,600 warrants
  • As of Nov 9, 2026: 26,976,625 shares outstanding
  • 19 offering/registration filings in last 24 months, including this one

Financial Impact

Zero revenue; net loss of $3,890,550 for nine months ended Sept 30, 2026; working capital deficit of $5,788,170; cash of $11,294; $3,387,500 gross raised via convertible notes on Oct 30, 2026

revenuenet lossworking capitalcashdilution

Risk Factors

  • Going concern risk: substantial doubt about ability to continue operations
  • Severe liquidity constraints with only $11,294 cash as of Sept 30, 2026
  • High dilution risk from 19 offering/registration filings in 24 months and outstanding convertible notes and warrants
  • Zero revenue with no near-term path to profitability
  • Material weakness in internal controls over financial reporting

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
424B4 Filing (ABVC), Batch item 10001213900-26-119790
Document: 0001213900-26-119790-index-headers.html0001213900-26-119791
Document: 0001213900-26-119790-index.html0001213900-26-119789
Document: 0001213900-26-119790.txt0001213900-26-119788
424B4 Filing (ABVC), Batch item 50001213900-26-119791
424B4 Filing (ABVC), Batch item 60001213900-26-119789

Track record

8 reports on ABVC

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +41.67% at T+60 after the Jul 2, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago 424B4 Bearish 6/10 Viewing Entry $0.9700 Now $0.9400 +3.09% settles Dec 15
  2. Nov 10, 20266d ago S-3/A Bearish 5/10 Entry $0.9921 Now $0.9400 +5.25% settles Dec 10
  3. Nov 2, 202614d ago Press Release Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
  4. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
  5. Sep 29, 20266w ago DEF 14A Bearish 6/10 Entry $1.04 to $1.05 Now $0.9400 +9.62% ▼ −0.96% −0.25% vs SPY
  6. Aug 3, 202615w ago 8-K Neutral 3/10 Entry $1.07 to $0.8254 Now $0.9400 −12.15% ▼ −22.86% −21.62% vs SPY
  7. Jul 2, 202619w ago 8-K Bearish 6/10 Entry $1.80 to $1.08 Now $0.9400 +47.78% ▲ +40.00% +39.59% vs SPY
  8. Mar 3, 202636w ago 8-K Bearish 8/10 Entry $1.45 to $1.08 Now $0.9400 +35.17% ▲ +25.52% +21.10% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 9h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026